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Hypercalcemia in patients with cancer is a common laboratory finding affecting up to 44% of that patient population. 1,25Dihydroxyvitamin D3 mediated hypercalcemia is one of the rare mechanisms of this endocrine emergency in cancer patients. It is
even rarer for solid organ neoplasms to present with hypercalcemia mediated through the production of 1,25-dihydroxyvitamin D3 .
We report a case of a 77-year-old female who presented to the hospital with hypercalcemia and later was found to have metastatic
gastrointestinal stromal tumor. There have been only 5 cases of gastrointestinal stromal tumor described in literature resulting in
hypercalcemia. In our case, the mechanism of hypercalcemia was thought to be related to overproduction of 1,25-dihydroxyvitamin
by tumor cells. The patient had a favorable response to imatinib with normalization of serum calcium level. Unfortunately, she
developed fluid retention due to imatinib which was discontinued resulting in relapse of hypercalcemia that was resistant to all
other treatment options.

1. Introduction
Hypercalcemia of malignancy is the most common cause
of hypercalcemia in hospitalized patients, while primary
hyperparathyroidism is the most common cause in ambulatory patients. Hypercalcemia in patients with cancer is
a common laboratory finding affecting up to 44% of that
patient population [1–3]. It is common in advanced stages
of cancer pertaining poor prognosis and survival [4]. The
most common (80%) mechanism is through secretion of
parathyroid hormone related peptide (PTH-rP) by tumors
cells followed by bone metastasis in the remaining majority
of cases (20%). Much less common mechanisms (<1% combined) are related to secretion of 1,25-dihydroxyvitamin D3
(1,25(OH)2 D3 or calcitriol) and parathyroid hormone (PTH)
by tumors cells [5].

2. Case Presentation
A 77-year-old female with history of hypertension presented
to the hospital with the chief complaint of progressive

weakness and confusion which started 3-4 days prior to
presentation. Patient denied any other complaints. Her vital
signs were within normal limits. Her physical examination was unremarkable. Her only home medication was
lisinopril for hypertension. Upon initial investigation, she
was found to have hypercalcemia of 15 mg/dL (reference
range: 8.5–10.6 mg/dL) and acute kidney injury (AKI) with
creatinine of 1.76 mg/dL (reference range: 0.4–1.0). The rest
of the comprehensive metabolic profile was normal.
Patient was started on intravenous (IV) fluids for the
management of hypercalcemia and AKI and the workup of hypercalcemia was initiated. Parathyroid hormone
(PTH), PTH-rP, 25(OH)D3 , calcitriol, and urine and serum
electrophoresis were ordered. PTH was 7.9 pg/mL (reference range: 10–65), PTH-rP was normal, 25(OH)D3 was
normal, and calcitriol was elevated at 129 (reference range
19.9–79.3 pg/mL). Serum and urine electrophoresis were
normal.
Patient underwent computer tomography (CT) of the
chest, abdomen, and pelvis to further investigate the cause of
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Figure 1: 20x micrographs, (a–d). Spindle cell neoplasm (a) is more cellular when compared to surrounding liver tissue (b). The tumor cells
of spindle cell neoplasm (a) appear uniform, with monomorphic nuclei and eosinophilic cytoplasm. Tumor cells stain strongly positive for
CD117 (c) and DOG1 (d).

hypercalcemia. CT chest was normal, but noncontrast CT of
abdomen showed multiple hepatic lesions and diffuse nodular thickening of the peritoneum consistent with peritoneal
carcinomatosis. PET/CT scan of the neck, chest, abdomen,
and pelvis demonstrated widespread hepatic and peritoneal
metastatic disease with small bilateral hypermetabolic pleural
effusions. Due to excessive metastasis the primary location of
tumor was not identified.
Patient underwent ultrasound guided percutaneous
biopsy of liver showing spindle cell neoplasm, consistent
with gastrointestinal stromal tumor (GIST). Immunohistochemical stains showed that tumor cells are positive for CD117
and DOG1 and negative for pancytokeratin, hepatocytic
specific antigen, S-100, and SMA, supporting the above diagnosis (Figure 1). The specimen was also evaluated for GIST
gene mutation analysis showing the presence of KIT gene
mutation (affecting exon 9 c.1502_1503insTGCCTA/p.Tyr503_
Phe504insAlaTyr) and absence of PDGFRA mutation.
Initially hypercalcemia was treated with IV fluids; after
diagnosis of metastatic GIST was made, imatinib (400 mg
once daily and then advanced to 400 mg twice daily) was
started. Upon discharge, patient’s Ca level and vitamin
D and kidney function were normalized. Repeat PET/CT
showed interval decrease in FDG uptake of hepatic metastatic
lesions. Since the initial hospitalization, she has had multiple
readmissions for fluid retention related to imatinib. Patient
was taken off imatinib because of side effects resulting in

relapse of hypercalcemia and increase in calcitriol that did
not respond to trial of calcitonin, steroids, zoledronic acid,
and denosumab. In the meantime, patient was started on
nilotinib (second-generation Tyrosine Kinase Inhibitor) but
unfortunately her condition continued to deteriorate and she
was subsequently transitioned to hospice care.

3. Discussion
Vitamin D3 (cholecalciferol) is synthesized in the skin under
the influence of ultraviolet light from 7-dehydrocholesterol
[6]. Subsequently, Vitamin D3 bound to vitamin D binding
protein enters the circulation and undergoes hydroxylation to
25-hydroxyvitamin D3 (25(OH)D3 ) in the liver through the
action of vitamin D3 -25-hydroxylase enzyme [7]. 25(OH)D3
is the major circulating form of vitamin D3. In the kidneys
enzyme 25-hydroxyvitamin D3 -1-hydroxylase (PTH dependent action) converts 25(OH)D3 to its metabolically active
form 1,25-dihydroxyvitamin D3 (calcitriol) [8]. Calcitriol
increases calcium and phosphorus absorption from intestine
(duodenum and proximal small intestine) and also promotes
mobilization of calcium from bone [9, 10].
Excessive production of vitamin D metabolites is one
of the mechanisms of vitamin D induced hypercalcemia.
Ectopic (extrarenal) production of calcitriol is the main
mechanisms of hypercalcemia in granulomatous diseases
(like sarcoidosis and tuberculosis) and lymphomas. In these
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cases, 25-hydroxyvitamin D3 -1-hydroxylase present in pulmonary alveolar macrophages and lymphocytes is responsible for conversion of 25(OH)D3 to 1,25(OH)2 D3 [11–
15]. Sarcoidosis was the most common cause of calcitriol
mediated hypercalcemia in the largest cohort of patients.
Hematological malignancies (17%) and infectious (8%) and
solid organ malignancies (5%) represented the less common
etiologies [16].
Our search identified only 5 cases of GIST related hypercalcemia in the English literature. In two of those cases the
mechanism of hypercalcemia was thought to be related to
overproduction of calcitriol, in one case the production of
PTH-rP was the cause, and in the remaining two cases no
mechanism was identified. [17–21]. In one of those cases GIST
gene mutation analysis showed the presence of KIT gene
mutation affecting exon 9 (no data was available regarding
the type of mutation) and absence of PDGFRA mutation
[19]. No molecular profile data were found in the remaining
four cases [17, 18, 20, 21]. In our case the two most common
causes of hypercalcemia of malignancy such as secretion of
PTH-rP and bone metastasis were excluded by negative PTHrP values and PET-CT scan. Hyperparathyroidism was also
ruled out by decreased level of PTH. Other cancers and
multiple myeloma were ruled out by negative results of PETCT scan and the absence of monoclonal protein in serum and
urine. The only mechanism that could explain hypercalcemia
in our case was increased production of calcitriol by tumor
cells. The proof of this theory is elevated level of calcitriol
upon initial presentation that was corrected posttreatment
with imatinib followed by relapse of hypercalcemia and
increased serum concentration of calcitriol when patient was
taken off imatinib due to side effects.
GISTs are mesenchymal neoplasms that most commonly
arise in the stomach and small intestine and comprise only 1%
of cancers primarily arising in the gastrointestinal tract [22,
23]. The annual incidence in the United States is 4000–6000
cases, with average age of diagnosis being 63 [24]. As a
group (>90%) they are defined by activating mutations in KIT
gene producing significant amounts of KIT transmembrane
receptor tyrosine kinase (RTK) [25]. However, in minority
of cases GISTs are KIT negative; in those cases activating
mutations in another gene, the platelet-derived growth factor
receptor alpha (PDGFRA) genes are responsible for encoding
an RTK [23]. Most commonly they arise from the stomach
(40–60%) and jejunum/ileum (25–30%). Duodenum, esophagus, and colorectum are less common sites [24]. Before
2001, surgery was the only available treatment for patients
with GIST, but management of GIST dramatically improved
since the understanding of the role of KIT/PDGFRA genes
in the molecular pathogenesis of GISTs leading to effective
systemic therapy with small molecule inhibitors of tyrosine
kinase receptors of which imatinib is considered prototype
drug [26–28].

4. Conclusion
Hypercalcemia from gastrointestinal stromal tumor is a rare
but serious endocrine emergency which needs immediate
treatment. Tyrosine Kinase Inhibitors are the recommended
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initial treatment for metastatic gastrointestinal stromal tumor
with KIT gene mutation. Our patient had a decrease in size
of metastatic lesions and calcitriol levels after therapy with
imatinib. Hence early diagnosis and GIST gene mutation
analysis are crucial in initiating appropriate treatment.
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